Blue Water Vaccines Announces Closing of $8 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Apr 20, 2022 | Press Releases

Proceeds To Fund Research and Development of BWV-101, BWV-102 and BWV-103CINCINNATI, April 20, 2022 — Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing...

Blue Water Vaccines Announces $8 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Apr 13, 2022 | Press Releases

Proceeds To Fund Research and Development of BWV-101, BWV 102 and BWV-103.CINCINNATI, April 13, 2022 — Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing...

Blue Water Vaccines Announces $8 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Apr 13, 2022 | Press Releases

Proceeds To Fund Research and Development of BWV-101, BWV 102 and BWV-103.CINCINNATI, April 13, 2022 — Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing...

Blue Water Vaccines Inc to Present at World Vaccine Congress Washington 2022

Apr 11, 2022 | Press Releases

BWV-101 – Universal Influenza Program: Developing a novel vaccine to protect against all influenza strains using groundbreaking mathematical models and research CINCINNATI, April 11, 2022 — Blue Water Vaccines Inc. (“BWV” or “Blue Water...

Blue Water Vaccines Announces Publication in Nano Research Supporting Novel S&P Vaccine Platform Versatility

Mar 22, 2022 | Press Releases

Blue Water Vaccines has exclusive, global licensing rights to Cincinnati Children’s Hospital Medical Center’s novel virus-like particle (VLP) vaccine platform.The data supports BWV’s ongoing development of a transformational universal influenza...

Blue Water Vaccines Announces Publication in Nano Research Supporting Novel S&P Vaccine Platform Versatility

Mar 22, 2022 | Press Releases

Blue Water Vaccines has exclusive, global licensing rights to Cincinnati Children’s Hospital Medical Center’s novel virus-like particle (VLP) vaccine platform.The data supports BWV’s ongoing development of a transformational universal influenza...